Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Feb 16;10(2):e00991.
doi: 10.14309/crj.0000000000000991. eCollection 2023 Feb.

Refractory Malignant Eosinophilic Colitis Leading to Ischemic Colitis

Christina Awad  1 , Benjamin Bailes  2 , Christian Horn  1 , Anish Patel  1
Affiliations
Case Reports

Refractory Malignant Eosinophilic Colitis Leading to Ischemic Colitis

Christina Awad et al. ACG Case Rep J. .

Abstract

Eosinophilic colitis (EC) is the most uncommon disease within the spectrum of eosinophilic gastrointestinal disorders. Currently, there are no well-established diagnostic criteria and no approved Food and Drug Administration therapies. We discuss a case of a 30-year-old man with refractory malignant EC leading to ischemic colitis. The patient was tried on multiple therapies, including a combination therapy of benralizumab and vedolizumab, which were unsuccessful. Unfortunately, the patient ultimately required a total proctocolectomy. More studies need to be performed to treat patients with severe refractory cases of EC.

Keywords: benralizumab; eosinophilia; eosinophilic colitis; ischemic colitis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(a) Endoscopic image of a flexible sigmoidoscopy showed friability, contact bleeding, surface ulceration, and sloughing of mucosa. (b) Abdominal CT showing thrombus (red arrow) at the portosplenic confluence extending into the main portal vein with associated heterogeneous appearance of the liver. (c) Repeat flexible sigmoidoscopy showed diffuse severe erythema, contact bleeding, and friable mucosa throughout the rectal pouch.
See this image and copyright information in PMC

References

    1. Gonsalves N. Eosinophilic gastrointestinal disorders. Clinic Rev Allerg Immunol. 2019;57(2):272–85. - PubMed
    1. Peterson K, Safroneeva E, Schoepfer A. Emerging therapies for eosinophilic gastrointestinal diseases. J Allergy Clin Immunol Pract. 2021;9(9):3276–81. - PubMed
    1. Kim HP, Reed CC, Herfarth HH, Dellon ES. Vedolizumab treatment may reduce steroid burden and improve histology in patients with eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2018;16(12):1992–4. - PMC - PubMed

Publication types